No deal: Report asserts that Roche has dropped any plans for Chugai buyout

The news that Roche ($RHHBY) struck a deal to buy InterMune ($ITMN) for $8.3 billion reportedly came at the expense of Chugai's investors. Roche had earlier been kicking around a deal to buy out the remaining stake in Chugai it doesn't already own for about $10 billion. But the InterMune deal took precedence and now Roche will leave Chugai alone, reports Bloomberg. Chugai, for its part, said there never was a deal on the table. And Roche CEO Severin Schwan had earlier ruled out an offer. Chugai's shares took a hit as investors finally got the message: No deal. Report

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.